SHS sells leading c-LEcta GmbH to Kerry Group
The Tübingen-based growth investor SHS announces the sale of its stake in the technology leader in enzyme engineering, c-LEcta GmbH.
The Irish Kerry Group, a leading global taste and nutrition partner for food, beverage and pharmaceutical markets, acquires the Leipzig-based company.
Thomas Pfaadt, CFO and Managing Director (l.); Carsten Fietz, Senior Vice President Finance & Administration (m.); Dr. Marc Struhalla, CEO and Managing Director (r.)
Today, c-LEcta is a leading innovator and supplier of biotech products for regulated markets such as food and pharmaceuticals. With over one hundred employees and world-class technologies for novel and cost-efficient industrial manufacturing processes, c-LEcta is one of the fastest growing companies in the market. Together with the strategic buyer, c-LEcta aims to further expand its range of bio-actives for food and pharmaceutical markets. SHS has invested in c-LEcta as a lead investor and has successfully driven the development of its products to market maturity and the international expansion of the company.
“SHS has been instrumental in supporting us with capital and strategic input on our journey to become a leading enzyme product provider. With the new partner Kerry Group, we want to take another growth step in our company’s history and are looking forward to the cooperation,” says c-LEcta CEO Marc Struhalla.
“We are pleased to have contributed to the tremendous growth of the company. Today, c-LEcta is an internationally important supplier for the pharmaceutical, chemical and food industries. We look back with pleasure on the journey we have taken together and wish the entire team continued success on their chosen path of growth,” comments SHS Managing Partner Uwe Steinbacher.
SHS has invested in c-LEcta from the third generation of SHS funds accompanied by a SHS co-investment fund refinanced by KfW.